193 related articles for article (PubMed ID: 37079393)
1. Reduced Respiratory Syncytial Virus Load, Symptoms, and Infections: A Human Challenge Trial of MVA-BN-RSV Vaccine.
Jordan E; Kabir G; Schultz S; Silbernagl G; Schmidt D; Jenkins VA; Weidenthaler H; Stroukova D; Martin BK; De Moerlooze L
J Infect Dis; 2023 Oct; 228(8):999-1011. PubMed ID: 37079393
[TBL] [Abstract][Full Text] [Related]
2. Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults.
Green CA; Sande CJ; Scarselli E; Capone S; Vitelli A; Nicosia A; Silva-Reyes L; Thompson AJ; de Lara CM; Taylor KS; Haworth K; Hutchings CL; Cargill T; Angus B; Klenerman P; Pollard AJ
J Infect; 2019 May; 78(5):382-392. PubMed ID: 30742894
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of novel modified vaccinia Ankara-vectored RSV vaccine: A randomized phase I clinical trial.
Samy N; Reichhardt D; Schmidt D; Chen LM; Silbernagl G; Vidojkovic S; Meyer TP; Jordan E; Adams T; Weidenthaler H; Stroukova D; De Carli S; Chaplin P
Vaccine; 2020 Mar; 38(11):2608-2619. PubMed ID: 32057576
[TBL] [Abstract][Full Text] [Related]
4. Broad Antibody and Cellular Immune Response From a Phase 2 Clinical Trial With a Novel Multivalent Poxvirus-Based Respiratory Syncytial Virus Vaccine.
Jordan E; Lawrence SJ; Meyer TPH; Schmidt D; Schultz S; Mueller J; Stroukova D; Koenen B; Gruenert R; Silbernagl G; Vidojkovic S; Chen LM; Weidenthaler H; Samy N; Chaplin P
J Infect Dis; 2021 Mar; 223(6):1062-1072. PubMed ID: 32726422
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phase 1 clinical trial in healthy adults.
Green CA; Scarselli E; Voysey M; Capone S; Vitelli A; Nicosia A; Cortese R; Thompson AJ; Sande CS; de Lara C; Klenerman P; Pollard AJ
BMJ Open; 2015 Oct; 5(10):e008748. PubMed ID: 26510727
[TBL] [Abstract][Full Text] [Related]
6. Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults.
Green CA; Scarselli E; Sande CJ; Thompson AJ; de Lara CM; Taylor KS; Haworth K; Del Sorbo M; Angus B; Siani L; Di Marco S; Traboni C; Folgori A; Colloca S; Capone S; Vitelli A; Cortese R; Klenerman P; Nicosia A; Pollard AJ
Sci Transl Med; 2015 Aug; 7(300):300ra126. PubMed ID: 26268313
[TBL] [Abstract][Full Text] [Related]
7. Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study.
Schmoele-Thoma B; Zareba AM; Jiang Q; Maddur MS; Danaf R; Mann A; Eze K; Fok-Seang J; Kabir G; Catchpole A; Scott DA; Gurtman AC; Jansen KU; Gruber WC; Dormitzer PR; Swanson KA
N Engl J Med; 2022 Jun; 386(25):2377-2386. PubMed ID: 35731653
[TBL] [Abstract][Full Text] [Related]
8. A Recombinant MVA-Based RSV Vaccine Induces T-Cell and Antibody Responses That Cooperate in the Protection Against RSV Infection.
Endt K; Wollmann Y; Haug J; Bernig C; Feigl M; Heiseke A; Kalla M; Hochrein H; Suter M; Chaplin P; Volkmann A
Front Immunol; 2022; 13():841471. PubMed ID: 35774800
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial.
Walsh SR; Wilck MB; Dominguez DJ; Zablowsky E; Bajimaya S; Gagne LS; Verrill KA; Kleinjan JA; Patel A; Zhang Y; Hill H; Acharyya A; Fisher DC; Antin JH; Seaman MS; Dolin R; Baden LR
J Infect Dis; 2013 Jun; 207(12):1888-97. PubMed ID: 23482644
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R;
Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361
[TBL] [Abstract][Full Text] [Related]
11. Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study.
Sadoff J; De Paepe E; DeVincenzo J; Gymnopoulou E; Menten J; Murray B; Rosemary Bastian A; Vandebosch A; Haazen W; Noulin N; Comeaux C; Heijnen E; Eze K; Gilbert A; Lambkin-Williams R; Schuitemaker H; Callendret B
J Infect Dis; 2022 Aug; 226(3):396-406. PubMed ID: 33400792
[TBL] [Abstract][Full Text] [Related]
12. Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial.
Bebia Z; Reyes O; Jeanfreau R; Kantele A; De Leon RG; Sánchez MG; Banooni P; Gardener GJ; Rasero JLB; Pardilla MBE; Langley JM; Di Leo CM; Botelho-Nevers E; Buttery J; Laurichesse H; Madhi SA; García AM; Stanley T; Barjat T; Griffith R; Castrejón-Alba MM; de Heusch M; Dieussaert I; Hercor M; Lese P; Qian H; Tullio AN; Henry O
J Infect Dis; 2023 Aug; 228(3):299-310. PubMed ID: 36722147
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged ≥60 Years.
Williams K; Bastian AR; Feldman RA; Omoruyi E; de Paepe E; Hendriks J; van Zeeburg H; Godeaux O; Langedijk JPM; Schuitemaker H; Sadoff J; Callendret B
J Infect Dis; 2020 Aug; 222(6):979-988. PubMed ID: 32320465
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of an Ad26.RSV.preF-RSV preF Protein Vaccine in Older Adults.
Falsey AR; Williams K; Gymnopoulou E; Bart S; Ervin J; Bastian AR; Menten J; De Paepe E; Vandenberghe S; Chan EKH; Sadoff J; Douoguih M; Callendret B; Comeaux CA; Heijnen E;
N Engl J Med; 2023 Feb; 388(7):609-620. PubMed ID: 36791161
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of a respiratory syncytial virus prefusion F protein (RSVPreF3) candidate vaccine in older Japanese adults: A phase I, randomized, observer-blind clinical trial.
Kotb S; Haranaka M; Folschweiller N; Nakanwagi P; Verheust C; De Schrevel N; David MP; Mesaros N; Hulstrøm V
Respir Investig; 2023 Mar; 61(2):261-269. PubMed ID: 36641341
[TBL] [Abstract][Full Text] [Related]
16. Early evaluation of the safety, reactogenicity, and immune response after a single dose of modified vaccinia Ankara-Bavaria Nordic vaccine against mpox in children: a national outbreak response.
Ladhani SN; Dowell AC; Jones S; Hicks B; Rowe C; Begum J; Wailblinger D; Wright J; Owens S; Pickering A; Shilltoe B; McMaster P; Whittaker E; Zuo J; Powell A; Amirthalingam G; Mandal S; Lopez-Bernal J; Ramsay ME; Kissane N; Bell M; Watson H; Ho D; Hallis B; Otter A; Moss P; Cohen J
Lancet Infect Dis; 2023 Sep; 23(9):1042-1050. PubMed ID: 37336224
[TBL] [Abstract][Full Text] [Related]
17. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS
J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602
[TBL] [Abstract][Full Text] [Related]
18. A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects.
Greenberg RN; Hay CM; Stapleton JT; Marbury TC; Wagner E; Kreitmeir E; Röesch S; von Krempelhuber A; Young P; Nichols R; Meyer TP; Schmidt D; Weigl J; Virgin G; Arndtz-Wiedemann N; Chaplin P
PLoS One; 2016; 11(6):e0157335. PubMed ID: 27327616
[TBL] [Abstract][Full Text] [Related]
19. Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial.
Milligan ID; Gibani MM; Sewell R; Clutterbuck EA; Campbell D; Plested E; Nuthall E; Voysey M; Silva-Reyes L; McElrath MJ; De Rosa SC; Frahm N; Cohen KW; Shukarev G; Orzabal N; van Duijnhoven W; Truyers C; Bachmayer N; Splinter D; Samy N; Pau MG; Schuitemaker H; Luhn K; Callendret B; Van Hoof J; Douoguih M; Ewer K; Angus B; Pollard AJ; Snape MD
JAMA; 2016 Apr; 315(15):1610-23. PubMed ID: 27092831
[TBL] [Abstract][Full Text] [Related]
20. An Adjuvanted, Postfusion F Protein-Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults.
Falloon J; Yu J; Esser MT; Villafana T; Yu L; Dubovsky F; Takas T; Levin MJ; Falsey AR
J Infect Dis; 2017 Dec; 216(11):1362-1370. PubMed ID: 29029260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
